419 related articles for article (PubMed ID: 22035157)
1. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
[TBL] [Abstract][Full Text] [Related]
2. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
5. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
[TBL] [Abstract][Full Text] [Related]
6. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.
Luger TA; Barker J; Lambert J; Yang S; Robertson D; Foehl J; Molta CT; Boggs R
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):896-904. PubMed ID: 19453794
[TBL] [Abstract][Full Text] [Related]
7. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial.
Thaçi D; Galimberti R; Amaya-Guerra M; Rosenbach T; Robertson D; Pedersen R; Yang S; Kuligowski M; Boggs R
J Eur Acad Dermatol Venereol; 2014 Jul; 28(7):900-6. PubMed ID: 23848989
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
10. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
[TBL] [Abstract][Full Text] [Related]
11. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
[TBL] [Abstract][Full Text] [Related]
12. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
Mrowietz U; Chouela EN; Mallbris L; Stefanidis D; Marino V; Pedersen R; Boggs RL
J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial.
van Riel PL; Freundlich B; MacPeek D; Pedersen R; Foehl JR; Singh A;
Ann Rheum Dis; 2008 Aug; 67(8):1104-10. PubMed ID: 17666447
[TBL] [Abstract][Full Text] [Related]
14. Disease characteristics in patients with and without psoriatic arthritis treated with etanercept.
Papp K; Poulin Y; Vieira A; Shelton J; Poulin-Costello M
J Eur Acad Dermatol Venereol; 2014 May; 28(5):581-9. PubMed ID: 23465037
[TBL] [Abstract][Full Text] [Related]
15. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
[TBL] [Abstract][Full Text] [Related]
17. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
18. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.
Kekow J; Moots R; Khandker R; Melin J; Freundlich B; Singh A
Rheumatology (Oxford); 2011 Feb; 50(2):401-9. PubMed ID: 21059675
[TBL] [Abstract][Full Text] [Related]
19. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.
Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F
Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600
[TBL] [Abstract][Full Text] [Related]
20. Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.
Boggs RL; Kárpáti S; Li W; Williams T; Pedersen R; Mallbris L; Gniadecki R
BMC Dermatol; 2014 Aug; 14():14. PubMed ID: 25091090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
